Dr Reddy’s

Dr Reddy’s and TR-Pharm in agreement

TR-Pharm will manufacture the drug substance and drug product upon completion of its facility investment in Turkey

Dr Reddy’s gets USFDA nod for migraine injection

The company has received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection, DRL said in a statement.

Dr Reddy’s gets USFDA nod for migraine injection

Pharma investors think small as US compliance woes hit heavyweights

Investors in India's $15 billion pharmaceutical industry are favouring smaller firms with little or no exposure to the United States.

Pharma investors think small as US compliance woes hit heavyweights

Dr Reddy’s gets USFDA extension for its response

The US Food and Drug Administration (USFDA) has granted Dr Reddy's Laboratories extension till December 7 for submitting its responses to the regulator's warning letter. The company is in the process of preparing the response

Retain ‘buy’ on Dr Reddy’s, target Rs 4,919: Nomura

Retain ‘buy’ on Dr Reddy's Laboratories and assign a target price of R 4,919 per share, valuing the stock at 23x our FY17-18f average EPS forecast of R214. The stock currently trades at 21x FY16F and 18.7x FY17f estimates

USFDA gives Dr Reddy’s additional time to respond to warning letter

Dr Reddy's Laboratories Ltd (DRL) today said the USFDA has extended the time-frame for replying to the warning letter issued to the company by about two weeks to December 7.

USFDA gives Dr Reddy’s additional time to respond to warning letter

USFDA warns of serious data integrity violations at Dr Reddy’s

The US Food and Drug Administration (USFDA) has warned Dr Reddy's Laboratories over serious data integrity violations, placing all its new applications or supplements under a cloud.

Dr Reddy’s launches Nise D Spray

The spray will likely be effective in reducing inflammation and pain

Dr Reddy’s launches Nexium generic in US market

Dr Reddy's Laboratories (DRL) has launched the generic version of Astrazeneca's Nexium, used to treat acid reflux, in the US market. (Reuters)

Dr Reddy’s launches Nexium generic in US market

Dr Reddy’s in pact with Australia firm

Dr Reddy’s Laboratories has signed a deal with Australian pharmaceutical company Hatchtech, to develop Xeglyze lotion...

Dr. Reddy’s in pact to sell Hatchtech hair lice lotion

Dr. Reddy’s Laboratories on Monday said it has signed a deal with Hatchtech, an Australian pharmaceutical company to sell the latter’s prescription head lice product, Xeglyze lotion. Dr. Reddy’s will have exclus

Dr. Reddy’s in pact to sell Hatchtech hair lice lotion

Dr Reddy’s recalls Rivastigmine Tartrate capsules from US

Dr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, following 'Failed Dissolution Specifications'.

Dr Reddy’s recalls Rivastigmine Tartrate capsules from US

Dr Reddy’s Q1 net up 14% at Rs 626 crore

Drug major Dr Reddy's Laboratories today reported a 13.67 per cent rise in its consolidated net profit to Rs 625.65 crore for the quarter ended June 30...

Dr Reddy’s Q1 net up 14% at Rs 626 crore

DRL unveils new corporate brand identity

The new identity speaks of Dr Reddy’s constant endeavour to understand the unmet and under-met needs of patients, and the swift action to solve them

Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

Advertisement
Advertisement

TRENDING NOW

BUDGET 2019

Related Articles